Atlas Trials

Apatinib Plus Irinotecan as Second-line Treatment in AGC or EGJA

Clinical trial NCT03116555 · UNKNOWN

Trial details

NCT number
NCT03116555
Sponsor
China Medical University, China
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Gastric Adenocarcinoma
Start date
2017-04-05
Primary completion
2020-03-01
Enrollment
37

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.